Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Shilpa Medicare Limited ( (IN:SHILPAMED) ) is now available.
Shilpa Medicare Limited announced that the United States Food and Drug Administration (USFDA) conducted an inspection at Unit-2 of its subsidiary, Shilpa Pharma Lifesciences Limited, from March 10-14, 2025. The inspection concluded with zero observations, marking the second consecutive time the facility has achieved this result, reinforcing the company’s strong compliance and operational standards.
More about Shilpa Medicare Limited
Shilpa Medicare Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of a wide range of pharmaceutical products. The company is known for its commitment to quality and compliance with international standards, serving both domestic and international markets.
YTD Price Performance: -23.04%
Average Trading Volume: 14,770
Current Market Cap: 63.1B INR
For a thorough assessment of SHILPAMED stock, go to TipRanks’ Stock Analysis page.